Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prostaglandin E1 decreases circulating endothelial cells

H Sinzinger1, P Fitscha, H Kritz

  • 1Department of Nuclear Medicine, University of Vienna, Austria.

Prostaglandins
|January 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Imaging of early carotid artery atherosclerotic lesions with 111In-labeled polyelonalhuman IgG (HIG)].

Nuklearmedizin. Nuclear medicine·2006
Same author

Endothelial dysfunction, atherosclerosis and diabetes.

Acta medica Austriaca·2001
Same author

6-oxo-PGF(1 alpha)and 8-epi-PGF(2 alpha)in the arterial wall layers of various species: a comparison between intact and atherosclerotic areas.

Prostaglandins, leukotrienes, and essential fatty acids·2001
Same author

[HDL-2000: A consensus. HDL--a neglected lipoprotein].

Wiener klinische Wochenschrift·2001
Same author

Association of lipoprotein(a), prostaglandin I(2)--synthesis stimulating plasma factor, biological half-life of prostaglandin I(2)and high-density lipoproteins in HIV-1 infection of different stages.

Prostaglandins, leukotrienes, and essential fatty acids·2000
Same author

[Unaltered homocysteine levels during simvastatin therapy].

Wiener klinische Wochenschrift·2000
Same journal

Tomoxiprole selectively inhibits cyclooxygenase-2.

Prostaglandins·1998
Same journal

Urinary thromboxane B2 in cardiac transplant patients as a screening method of rejection.

Prostaglandins·1998
Same journal

Occurrence of 13(S)-hydroxyoctadecadienoic acid in biological samples.

Prostaglandins·1998
Same journal

Nomenclature of isoprostanes: a proposal.

Prostaglandins·1998
Same journal

The isoprostanes: a perspective.

Prostaglandins·1998
Same journal

Time course study for airway inflammation and responsiveness by repeated provocation of aeroantigen in guinea pigs.

Prostaglandins·1998
See all related articles

Prostaglandin E1 (PGE1) therapy significantly reduced circulating endothelial cells (CEC) in peripheral vascular disease patients, indicating improved blood flow and reduced clotting. This beneficial effect on thrombogenicity persisted for over a month post-treatment.

Area of Science:

  • Vascular Biology
  • Pharmacology
  • Cardiovascular Medicine

Background:

  • Prostaglandin E1 (PGE1) is recognized for potential cytoprotective and anti-thrombotic properties.
  • Peripheral vascular disease (PVD) is often associated with endothelial dysfunction and increased thrombogenicity.
  • Circulating endothelial cells (CEC) serve as biomarkers for endothelial injury and vascular disease activity.

Purpose of the Study:

  • To investigate the impact of intraarterial (i.a.) and intravenous (i.v.) Prostaglandin E1 (PGE1) on circulating endothelial cell (CEC) counts in patients with peripheral vascular disease (PVD).
  • To assess the correlation between PGE1 administration, CEC levels, and platelet survival in PVD patients.

Main Methods:

  • PGE1 was administered via intraarterial and intravenous routes to patients diagnosed with peripheral vascular disease (PVD).

Related Experiment Videos

  • The number of circulating endothelial cells (CEC) was quantified before, during, and after PGE1 treatment.
  • Platelet survival was monitored concurrently with CEC measurements.
  • Patient data included status on hyperlipoproteinemia and smoking habits.

    • Main Results:

    • Patients with hyperlipoproteinemia and smokers presented with elevated baseline CEC counts.
    • PGE1 administration resulted in a statistically significant reduction (p < 0.01) in CEC numbers.
    • Platelet survival was significantly prolonged (correlation coefficient r = 0.82) during PGE1 therapy.
    • The observed decrease in CEC and improved platelet survival persisted for over one month after cessation of PGE1 treatment.

    Conclusions:

    • Intraarterial and intravenous PGE1 effectively reduces circulating endothelial cells (CEC) in patients with peripheral vascular disease (PVD).
    • The reduction in CEC suggests decreased endothelial damage and improved hemostasis.
    • PGE1 therapy demonstrates a sustained positive impact on thrombogenicity and vascular health in PVD patients.